Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
Authors
Keywords
Overall Survival, Pancreatic Cancer, Major Histocompatibility Complex Class, Pancreatic Ductal Adenocarcinoma, Antitumor Immune Response
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 21, Issue 2, Pages 670-676
Publisher
Springer Nature
Online
2013-12-06
DOI
10.1245/s10434-013-3390-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer
- (2012) Masayuki Sho et al. Journal of Hepato-Biliary-Pancreatic Sciences
- An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
- (2012) Laura Senovilla et al. OncoImmunology
- The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
- (2011) Takahiro Tsuchikawa et al. ANNALS OF SURGICAL ONCOLOGY
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
- (2011) Deyali Chatterjee et al. CANCER
- Neo-adjuvant Chemoradiation Therapy Using S-1 Followed by Surgical Resection in Patients with Pancreatic Cancer
- (2011) Sohei Satoi et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Impact of Histological Response After Neoadjuvant Chemoradiotherapy on Recurrence-Free Survival in UICC-T3 Pancreatic Adenocarcinoma But Not in UICC-T4
- (2011) Yasuhiro Murata et al. PANCREAS
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
- (2010) Suzanne Ostrand-Rosenberg CANCER IMMUNOLOGY IMMUNOTHERAPY
- Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer
- (2009) Hiroaki Ohigashi et al. ANNALS OF SURGERY
- Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer
- (2009) U. Zingg et al. EJSO
- Neoadjuvant Chemoradiation in Patients With Potentially Resectable Pancreatic Cancer
- (2009) Soichiro Takai et al. PANCREAS
- Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
- (2008) S. Ladoire et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
- (2008) Ilaria Marigo et al. IMMUNOLOGICAL REVIEWS
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started